Trade Names:Velosef- Capsules 250 mg- Capsules 500 mg- Powder for Oral Suspension 125 mg/5 mL- Powder for Oral Suspension 500 mg/5 mL
Inhibits mucopeptide synthesis in bacterial cell wall.
Cephradine is rapidly absorbed. C max is about 9 mcg/mL (250 mg) to 24.2 mcg/mL (1 g). T max is 1 h. Food delays absorption.
8% to 17% protein bound.
More than 90% is excreted unchanged in the urine. The t ½ is 48 to 80 min.
The t ½ is prolonged. Dosage adjustment is recommended.
Treatment of infections of respiratory tract, urinary tract, skin and skin structure; treatment of otitis media caused by susceptible strains of microorganisms.
Hypersensitivity to cephalosporins.
PO 250 mg to 1 g every 6 to 12 h.Children
PO 25 to 100 mg/kg/day in equally divided doses every 6 to 12 h (max, 4 g/day).
May administer without regard to meals. Administer with food or milk if GI upset occurs. Food slows but does not decrease absorption.
Reconstituted oral suspension may be stored at room temperature for up to 7 days or in refrigerator for 14 days. Shake well before pouring. When drug is stored at room temperature, protect from light.
Inhibition of renal excretion of cephradine.
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets but not with enzyme-based tests (eg, Clinistix , Testape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test result in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values; false-positive reactions in urinary protein tests that use sulfosalicylic acid.
Nausea; vomiting; diarrhea; colitis, including pseudomembranous colitis.
Renal dysfunction; pyuria; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
Eosinophilia; neutropenia; lymphocytosis; leukocytosis; decreased platelet function; anemia; aplastic anemia.
Hepatic dysfunction; abnormal LFT results.
Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness–like reactions (eg, skin rashes, polyarthritis, arthralgia, fever).
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not appear to improve or worsens.Adverse reactions
Monitor patient for GI, DERM, and general body adverse reactions, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Category B .
Excreted in breast milk.
Safety and efficacy for infants under 9 mo not established.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with renal function impairment. Monitor renal function and dosage adjusted.
Drug may result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Consider in patients in whom diarrhea develops.
Copyright © 2009 Wolters Kluwer Health.